Irritable Bowel Syndrome (IBS) Study

Now Open in Washington, D.C.

Now Enrolling

Children who have irritable bowel syndrome associated with constipation (IBS-C) and abdominal pain may qualify for a clinical study with Meridian Clinical Research. This study will gather additional information about the safety and effectiveness of a medication that is currently approved for use by adults with IBS-C.

All study-related office visits, study medications, lab work, and study procedures are provided at no cost to participants. This is a placebo-controlled study — some patients will receive a non-active placebo.

Eligible participants…

  • Must be age 6 to 17
  • Must have had the following symptoms for at least 2 months; Abdominal pain at least 4 days per month associated with one or more of the following:
    • Related to defecation
    • A change in frequency of stool
    • A change in form (appearance) of stool
  • Will receive compensation for study-related time
  • Do not need insurance to join this study

For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.

You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.

Study Location

Meridian Clinical Research
4850 Massachusetts Ave NW, 2nd Floor
Washington, DC 20016

Expect Excellence icon - supporting research since 1999

Submit Your Information

Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services.

Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.